Safety Profile of IBD Therapeutics: Infectious Risks

Medical Clinics of North America

Volumn 94, Issue 1, 2010, Pages 115-133

  Afif, Waqqas ^a   Loftus Jr , Edward V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Anti tumor necrosis factor; Corticosteroids; Immunomodulator; Infection; Inflammatory bowel disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGIC REACTION; ASPERGILLOSIS; BACTEREMIA; BACTERIAL INFECTION; BLASTOMYCOSIS; BONE MARROW TOXICITY; CANDIDIASIS; CHICKENPOX; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; EPSTEIN BARR VIRUS; FOOD AND DRUG ADMINISTRATION; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LISTERIOSIS; MORTALITY; MYCOSIS; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; PHARMACOEPIDEMIOLOGY; PNEUMOCYSTOSIS; PNEUMONIA; POPULATION RESEARCH; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; STREPTOCOCCUS INFECTION; TUBERCULOSIS; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS HEPATITIS; VIRUS INFECTION;

EID: 70450172575     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.08.016     Document Type: Review

References (120)

1. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn disease: an open randomised trial. Lancet 371 9613 (2008) 660-667
2. Sandborn W.J. Initial combination therapy in early Crohn disease. Lancet 371 9613 (2008) 635-636
3. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn disease: TREAT registry. Clin Gastroenterol Hepatol 4 5 (2006) 621-630
4. Toruner M., Loftus Jr. E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 4 (2008) 929-936
5. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn disease: the Mayo Clinic experience in 500 patients. Gastroenterology 126 1 (2004) 19-31
6. Reddy J.G., and Loftus Jr. E.V. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 35 4 (2006) 837-855
7. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 2 (2001) 255-260
8. Munkholm P., Langholz E., Davidsen M., et al. Frequency of glucocorticoid resistance and dependency in Crohn disease. Gut 35 3 (1994) 360-362
9. Silverstein M.D., Loftus E.V., Sandborn W.J., et al. Clinical course and costs of care for Crohn disease: Markov model analysis of a population-based cohort. Gastroenterology 117 1 (1999) 49-57
10. Munkholm P., Langholz E., Davidsen M., et al. Disease activity courses in a regional cohort of Crohn disease patients. Scand J Gastroenterol 30 7 (1995) 699-706
11. Lewis J.D., Bilker W.B., Brensinger C., et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 5 (2001) 1080-1087
12. Stuck A.E., Minder C.E., and Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11 6 (1989) 954-963
13. Malchow H., Ewe K., Brandes J.W., et al. European Cooperative Crohn Disease Study (ECCDS): results of drug treatment. Gastroenterology 86 2 (1984) 249-266
14. Agrawal A., Durrani S., Leiper K., et al. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn disease. Clin Gastroenterol Hepatol 3 12 (2005) 1215-1220
15. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 3 (2006) 935-939 940-87
16. Papi C., Luchetti R., Gili L., et al. Budesonide in the treatment of Crohn disease: a meta-analysis. Aliment Pharmacol Ther 14 11 (2000) 1419-1428
17. Pearson D.C., May G.R., Fick G., et al. Azathioprine for maintaining remission of Crohn disease. Cochrane Database Syst Rev 2 (2000) CD000067
18. Sandborn W., Sutherland L., Pearson D., et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn disease. Cochrane Database Syst Rev 2 (2000) CD000545
19. Timmer A., McDonald J.W., and Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 1 (2007) CD000478
20. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46 7 (2007) 1157-1160
21. Gisbert J.P., and Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103 7 (2008) 1783-1800
22. Lichtenstein G.R., Abreu M.T., Cohen R., et al. American Gastroenterological Associate Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 3 (2006) 940-987
23. Present D.H., Meltzer S.J., Krumholz M.P., et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111 8 (1989) 641-649
24. Warman J.I., Korelitz B.I., Fleisher M.R., et al. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn disease and ulcerative colitis. J Clin Gastroenterol 37 3 (2003) 220-225
25. Marrie T.J. [Community acquired pneumonia]. Praxis (Bern 1994) 90 21 (2001) 935-940 [in German]
26. Seksik P., Cosnes J., Sokol H., et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther 29 10 (2009) 1106-1113
27. Feagan B.G., Fedorak R.N., Irvine E.J., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn disease. North American Crohn Study Group Investigators. N Engl J Med 342 22 (2000) 1627-1632
28. Feagan B.G., Rochon J., Fedorak R.N., et al. Methotrexate for the treatment of Crohn disease. The North American Crohn Study Group Investigators. N Engl J Med 332 5 (1995) 292-297
29. Ardizzone S., Bollani S., Manzionna G., et al. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn disease: a randomised, investigator-blind study. Dig Liver Dis 35 9 (2003) 619-627
30. Lemann M., Zenjari T., Bouhnik Y., et al. Methotrexate in Crohn disease: long-term efficacy and toxicity. Am J Gastroenterol 95 7 (2000) 1730-1734
31. Din S., Dahele A., Fennel J., et al. Use of methotrexate in refractory Crohn disease: the Edinburgh experience. Inflamm Bowel Dis 14 6 (2008) 756-762
32. McLean-Tooke A., Aldridge C., Waugh S., et al. Methotrexate, rheumatoid arthritis and infection risk: what is the evidence?. Rheumatology (Oxford) 48 8 (2009) 867-871
33. Greenberg J.D., Reed G., Kremer J.M., et al. Association of Methotrexate and TNF antagonists with risk of infection outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis (2009) [Epub ahead of print]
34. Blonski W., and Lichtenstein G.R. Safety of biologic therapy. Inflamm Bowel Dis 13 6 (2007) 769-796
35. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 23 (2005) 2462-2476
36. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 19 (2006) 2275-2285
37. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6 6 (2008) 644-653
38. Lichtenstein G.R., Cohen R., Feagan B., et al. Safety of infliximab and other Crohn disease therapies-TREAT registry data with nearly 24,575 patient years of follow-up. [abstract]. Am J Gastroenterol 104 S1 (2008) 5436
39. Lees C.W., Ali A.I., Thompson A.I., et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 29 3 (2009) 286-297
40. Colombel J.F., Sandborn W.J., Panaccione R., et al. Adalimumab safety in global clinical trials of patients with Crohn disease. Inflamm Bowel Dis (2009) [Epub ahead of print]
41. Fidder H., Schnitzler F., Ferrante M., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 58 4 (2009) 501-508
42. Ljung T., Karlen P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 6 (2004) 849-853
43. Schneeweiss S., Korzenik J., Solomon D.H., et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 30 3 (2009) 253-264
44. Sandborn W., Rutgeerts P., Reinisch W., et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn disease naïve to immunomodulators and biologic therapy. [abstract]. Am J Gastroenterol 103 S1 (2008) 5436
45. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn disease. Gut 56 9 (2007) 1226-1231
46. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Benefits and risks of immunomodulators and maintenance infliximab for IBD: subgroup analyses across four randomized trials. Aliment Pharmacol Ther 30 3 (2009) 210-226
47. Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54 4 (2006) 1075-1086
48. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 344 8920 (1994) 423-428
49. Arts J., D'Haens G., Zeegers M., et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 10 2 (2004) 73-78
50. Maser E.A., Deconda D., Lichtiger S., et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 6 10 (2008) 1112-1116
51. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D 5 2 (2004) 102-107
52. Sandborn W.J., Colombel J.F., Enns R., et al. Natalizumab induction and maintenance therapy for Crohn disease. N Engl J Med 353 18 (2005) 1912-1925
53. Ghosh S., Goldin E., Gordon F.H., et al. Natalizumab for active Crohn disease. N Engl J Med 348 1 (2003) 24-32
54. Gordon F.H., Hamilton M.I., Donoghue S., et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 16 4 (2002) 699-705
55. Gordon F.H., Lai C.W., Hamilton M.I., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn disease. Gastroenterology 121 2 (2001) 268-274
56. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn disease. N Engl J Med 353 4 (2005) 362-368
57. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 4 (2005) 369-374
58. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 4 (2005) 375-381
59. Tysabri update. Available at:. http://www.biogenidec.com/site/tysabri-information-center.html Accessed June 9, 2009
60. Subramanian V., Saxena S., Kang J.Y., et al. Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery. Am J Gastroenterol 103 9 (2008) 2373-2381
61. Aberra F.N., Lewis J.D., Hass D., et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125 2 (2003) 320-327
62. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. Early postoperative complications are not increased in patients with Crohn disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99 5 (2004) 878-883
63. Mahadevan U., Loftus Jr. E.V., Tremaine W.J., et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 8 5 (2002) 311-316
64. Ferrante M., D'Hoore A., Vermeire S., et al. Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 15 7 (2009) 1062-1070
65. Kunitake H., Hodin R., Shellito P.C., et al. Perioperative treatment with infliximab in patients with Crohn disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 12 10 (2008) 1730-1736 [discussion: 1736-7]
66. Marchal L., D'Haens G., Van Assche G., et al. The risk of post-operative complications associated with infliximab therapy for Crohn disease: a controlled cohort study. Aliment Pharmacol Ther 19 7 (2004) 749-754
67. Schluender S.J., Ippoliti A., Dubinsky M., et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?. Dis Colon Rectum 50 11 (2007) 1747-1753
68. Selvasekar C.R., Cima R.R., Larson D.W., et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204 5 (2007) 956-962 [discussion: 962-3]
69. Mor I.J., Vogel J.D., da Luz Moreira A., et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51 8 (2008) 1202-1207 [discussion: 1207-10]
70. Swoger J.M., Loftus Jr. E.V., Pardi D.S., et al. Pre-operative infliximab exposure and the occurrence of post-operative complications following proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis. [abstract]. Gastroenterology 136 (2009) A188
71. Aberra F.N., Stettler N., Brensinger C., et al. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 5 9 (2007) 1070-1075
72. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3 3 (2003) 148-155
73. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48 8 (2003) 2122-2127
74. Askling J., Fored C.M., Brandt L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 7 (2005) 1986-1992
75. Wolfe F., Michaud K., Anderson J., et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50 2 (2004) 372-379
76. Keane J., Gershon S., Wise R.P., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 15 (2001) 1098-1104
77. Sichletidis L., Settas L., Spyratos D., et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10 10 (2006) 1127-1132
78. Rahier J.F., Ben-Horin S., Chowers Y., et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn Colitis (2009) 10.1016/j.crohns.2009.02.010
79. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60 (2005) 800-805
80. Theis V.S., and Rhodes J.M. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 27 (2008) 19-30
81. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38 9 (2004) 1261-1265
82. Gluck T., Linde H.J., Scholmerich J., et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 46 8 (2002) 2255-2257 [author reply 2257]
83. Kamath B.M., Mamula P., Baldassano R.N., et al. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 34 4 (2002) 410-412
84. Slifman N.R., Gershon S.K., Lee J.H., et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 48 2 (2003) 319-324
85. Singh S.M., Rau N.V., Cohen L.B., et al. Cutaneous nocardiosis complicating management of Crohn disease with infliximab and prednisone. CMAJ 171 9 (2004) 1063-1064
86. Kaur N., and Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 52 6 (2007) 1481-1484
87. Khatchatourian M., and Seaton T.L. An unusual complication of immunosuppressive therapy in inflammatory bowel disease. Am J Gastroenterol 92 9 (1997) 1558-1560
88. Takenaka R., Okada H., Mizuno M., et al. Pneumocystis carinii pneumonia in patients with ulcerative colitis. J Gastroenterol 39 11 (2004) 1114-1115
89. Smith M.B., and Hanauer S.B. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med 327 7 (1992) 497-498
90. Quan V.A., Saunders B.P., Hicks B.H., et al. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ 314 7077 (1997) 363-364
91. Seddik M., Meliez H., Seguy D., et al. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn disease. Inflamm Bowel Dis 10 4 (2004) 436-437
92. Tai T.L., O'Rourke K.P., McWeeney M., et al. Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) 41 8 (2002) 951-952
93. Velayos F.S., and Sandborn W.J. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn sdisease. Inflamm Bowel Dis 10 5 (2004) 657-660
94. Harigai M., Koike R., and Miyasaka N. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 357 18 (2007) 1874-1876
95. Lee J.H., Slifman N.R., Gershon S.K., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46 10 (2002) 2565-2570
96. Wood K.L., Hage C.A., Knox K.S., et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 167 9 (2003) 1279-1282
97. Food and drug administration Medwatch. Available at:. http://www.fda.gov/cder/drug/InfoSheets/HCP/TNF_blockersHCP.htm Accessed June 9, 2009
98. Bergstrom L., Yocum D.E., Ampel N.M., et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 50 6 (2004) 1959-1966
99. Belda A., Hinojosa J., Serra B., et al. [Systemic candidiasis and infliximab therapy]. Gastroenterol Hepatol 27 6 (2004) 365-367 [in Spanish]
100. De Rosa F.G., Shaz D., Campagna A.C., et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case?. Infect Control Hosp Epidemiol 24 7 (2003) 477-482
101. Gottlieb G.S., Lesser C.F., Holmes K.K., et al. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis 37 6 (2003) 838-840
102. van der Klooster J.M., Bosman R.J., Oudemans-van Straaten H.M., et al. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 29 12 (2003) 2327-2329
103. del Valle Garcia-Sanchez M., Gomez-Camacho F., Poyato-Gonzalez A., et al. Infliximab therapy in a patient with Crohn disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10 5 (2004) 701-702
104. Millonig G., Kern M., Ludwiczek O., et al. Subfulminant hepatitis B after infliximab in Crohn disease: need for HBV-screening?. World J Gastroenterol 12 6 (2006) 974-976
105. Cheng A.L., Hsiung C.A., Su I.J., et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 37 6 (2003) 1320-1328
106. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 2 (2007) 507-539
107. Cepeda E.J., Williams F.M., Ishimori M.L., et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67 5 (2008) 710-712
108. Kaur P.P., Chan V.C., and Berney S.N. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. J Clin Rheumatol 13 2 (2007) 79-80
109. Wallis R.S., Kyambadde P., Johnson J.L., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18 2 (2004) 257-264
110. Markowitz L.E., Dunne E.F., Saraiya M., et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 56 RR-2 (2007) 1-24
111. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2009. Ann Intern Med 150 1 (2009) 40-44
112. Saag K.G., Koehnke R., Caldwell J.R., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96 2 (1994) 115-123
113. Bargallo A., Carrion S., Domenech E., et al. [Infectious mononucleosis in patients with inflammatory bowel disease under treatment with azathioprine]. Gastroenterol Hepatol 31 5 (2008) 289-292 [in Spanish]
114. Reijasse D., Le Pendeven C., Cosnes J., et al. Epstein-Barr virus viral load in Crohn disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 10 2 (2004) 85-90
115. Haerter G., Manfras B.J., de Jong-Hesse Y., et al. Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 39 9 (2004) e88-e94
116. Helbling D., Breitbach T.H., and Krause M. Disseminated cytomegalovirus infection in Crohn disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 14 12 (2002) 1393-1395
117. Kandiel A., and Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 101 12 (2006) 2857-2865
118. Papadakis K.A., Tung J.K., Binder S.W., et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 96 7 (2001) 2137-2142
119. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn disease. N Engl J Med 350 9 (2004) 876-885
120. Torre-Cisneros J., Del Castillo M., Caston J.J., et al. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology (Oxford) 44 9 (2005) 1132-1135